Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
Valbenazine appeared to be well tolerated in adults with TD who received up to 48 weeks of treatment. In addition to long-term efficacy results (presented separately), these results suggest that valbenazine may be appropriate for the long-term management of TD regardless of underlying psychiatric diagnosis (SCHZ disorder or mood disorder).
Authors
- John M. Kane (ORCID: https://orcid.org/0000-0002-2628-9442)
- Richard C. Josiassen (ORCID: https://orcid.org/0000-0002-2572-975X)
- Grace Liang (ORCID: https://orcid.org/0009-0008-2581-4891)
- Joshua Burke
- Christopher O’Brien
Institutions
- Hofstra University (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4365
- Citations
- 23
- Primary Topic
- Attention Deficit Hyperactivity Disorder
- Type
- article
- Field-Weighted Citation Impact
- 2.94